Abstract:Mitochondrial abnormalities are crucial in the progression of systemic lupus erythematosus (SLE), with key elements like mitochondrial DNA mutations, oxidative stress, and immune metabolic reprogramming leading to cellular death. These dysfunctions result in an array of SLE symptoms, pointing toward mitochondrial pathways as potential therapeutic targets for improved patient outcomes. Systemic lupus erythematosus (SLE), a chronic autoimmune disease, is marked by impaired immune tolerance and heightened activity in both innate and adaptive immune systems. Hallmarks of SLE include elevated type I interferons and autoantibody production, though the exact causes of SLE remain elusive despite advances in research techniques. Crucial to SLE research is understanding its pathogenesis and developing effective diagnostic and therapeutic methods. Recent studies have highlighted a significant link between mitochondrial abnormalities and SLE's development and progression. Mitochondrial dysfunction plays a key role in SLE pathogenesis through various mechanisms such as mitochondrial DNA mutations, oxidative stress, immune metabolic reprogramming, and cellular death. These factors collectively contribute to the loss of self‐tolerance, increased autoantibody production, and impaired clearance of immune complexes, leading to their deposition. This triggers sustained inflammatory responses and damages multiple organs. This review focuses on the diagnostic and therapeutic approaches related to mitochondrial abnormalities in SLE. Targeting mitochondrial pathways presents a promising strategy for treating SLE, potentially improving prognosis and quality of life for those affected. Future research should further investigate the role of mitochondria in the onset and progression of SLE, providing new avenues for understanding and managing this complex disease.

Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis

The Gut Microbiota and Associated Metabolites in Multiple Sclerosis

Mitochondrial Dysfunction in Microglia: a Novel Perspective for Pathogenesis of Alzheimer’s Disease

The role of the "gut microbiota-mitochondria" crosstalk in the pathogenesis of multiple sclerosis

Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review)

Myeloid-derived Suppressor Cells and Multiple Sclerosis

Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis

Impaired metabolism of oligodendrocyte progenitor cells and axons in demyelinated lesion and in the aged CNS

Mitochondrial dysfunction in myasthenia gravis: Exploring directions for future immunotherapy? A review

Mitochondrial aberrations in systemic lupus erythematosus pathogenesis: Insights and therapeutic implications

Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications

Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus

Role of autophagy in the pathogenesis of multiple sclerosis

Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases

Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis

Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

Autophagy Modulation in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

CD4+ T cell mitochondrial genotype in Multiple Sclerosis: a cross-sectional and longitudinal analysis

Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis.